

IQVIA announces alliance with FDA-CBER

07 February 2018 | News

The objective is to combine advanced analytics and unparalleled information assets to monitor and assist in the evaluation of safety and effectiveness of various CBER-regulated vaccines, blood products and other biologics.

IQVIA CORE™



A company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, IQVIA has entered into an alliance with the FDA Center for Biologics Evaluation and Research (CBER).

The objective is to combine advanced analytics and unparalleled information assets to monitor and assist in the evaluation of safety and effectiveness of various CBER-regulated vaccines, blood products and other biologics.

In this regard, IQVIA has teamed up with the Observational Health Data Science and Informatics (OHDSI) initiative and its world-class team of healthcare experts and unique data assets from Columbia University, Stanford University, Georgia Institute of Technology, University of California, Los Angeles (UCLA) and the Regenstrief Institute at the Indiana University School of Medicine to enhance the function and outputs of the initiative.

IQVIA brings its IQVIA CORE to the agreement, leveraging one of the world's largest curated healthcare information sources, advanced analytics, leading technologies and extensive industry knowledge across diseases, geographies and scientific methods.